Shareholders approved the 2025 Equity Compensation Plan, initially reserving 891,316 shares of common stock for issuance, with an evergreen formula for annual increases up to 2% of outstanding shares (maximum 300,000 shares). T. Ronan Kennedy, CEO and CFO, was granted 445,000 restricted stock shares, which are now issued following the 2025 Plan's approval. Seven directors were elected to hold office until the 2027 annual meeting of shareholders. The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2026, was ratified. Shareholders approved an amendment to the company's articles of incorporation to effect a reverse stock split, at the board's discretion, ranging from one-for-two (1:2) to one-for-ten (1:10), within one year. Approval was granted for the issuance of shares upon conversion of Series B Convertible Preferred Stock and accrued dividends, potentially resulting in significant dilution to existing shareholders (more than 20% of outstanding common stock). Approval was granted for the issuance of shares upon conversion of Series C Convertible Preferred Stock and accrued dividends, potentially resulting in significant dilution to existing shareholders (more than 20% of outstanding common stock). Approval was granted for the issuance of shares under an equity line of credit (ELOC Agreement) with C/M Capital Master Fund, LP, potentially resulting in significant dilution to existing shareholders (more than 20% of outstanding common stock).